Details for Patent: 9,555,023
✉ Email this page to a colleague
Which drugs does patent 9,555,023 protect, and when does it expire?
Patent 9,555,023 protects BEVYXXA and is included in one NDA.
This patent has thirty-one patent family members in twenty countries.
Summary for Patent: 9,555,023
| Title: | Pharmaceutical salts and polymorphs of a factor Xa inhibitor |
| Abstract: | The present invention provides for salts comprising a compound of Formula I and an acid that has activity against mammalian factor Xa. The present invention is also directed to methods of making the compound of Formula I. ##STR00001## |
| Inventor(s): | Grant; Craig (Burwell, GB), Kanter; James P. (San Ramon, CA), Langlands; Graeme (Soham, GB) |
| Assignee: | Millennium Pharmaceuticals, Inc. (Cambridge, MA) |
| Application Number: | 14/715,507 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Drugs Protected by US Patent 9,555,023
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-001 | Jun 23, 2017 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | PROPHYLAXIS OF PULMONARY EMBOLISM | ⤷ Sign Up | ||||
| Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-002 | Jun 23, 2017 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | PROPHYLAXIS OF PULMONARY EMBOLISM | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
